Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hairy Cell Leukemia variant (HCL-V) is defined as a rare and indolent form of small, mature, B-cell leukemia characterized by splenomegaly, an elevated white blood cell (WBC) count and hyper-cellular bone marrow. HCL-V is more aggressive and resistant to therapy than classical HCL (HCL-C).
Biomarker and diagnostic research for hairy cell leukemia variant has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
3 clinical trials registered. Interventions under study include drug therapy, procedural interventions, and biologic therapy. Pipeline includes 2 PHASE2, 1 PHASE1. Research is primarily sponsored by academic and government institutions.
35 publications have been identified in PubMed for hairy cell leukemia variant. Research spans Review / Meta-Analysis (27%), Case Report / Case Series (21%), and Basic Science / Preclinical (15%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 9 |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 11:54 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Patient case studies | 7 | 21% |
Laboratory research | 5 | 15% |
Clinical study results | 4 | 12% |
Disease patterns and progression | 4 | 12% |
Other research | 2 | 6% |
Testing and diagnosis research | 1 | 3% |
New treatment approaches | 1 | 3% |
Schroeder B (2026). [PMID: 41060318](https://pubmed.ncbi.nlm.nih.gov/41060318/). *Blood*. [Clinical Trial Publication]
Zent CS (2026). [PMID: 41980020](https://pubmed.ncbi.nlm.nih.gov/41980020/). *Blood*. [Review / Meta-Analysis]
Blombery P (2026). [PMID: 41528825](https://pubmed.ncbi.nlm.nih.gov/41528825/). *Leuk Lymphoma*. [Basic Science / Preclinical]
Bernardelli A (2026). [PMID: 42046272](https://pubmed.ncbi.nlm.nih.gov/42046272/). *Hematol Oncol*. [Case Report / Case Series]
Rehman A (2026). [PMID: 42109837](https://pubmed.ncbi.nlm.nih.gov/42109837/). *Case Rep Med*. [Case Report / Case Series]
Belkadi S (2026). [PMID: 42220746](https://pubmed.ncbi.nlm.nih.gov/42220746/). *Cureus*. [Case Report / Case Series]
Yan Y (2026). [PMID: 42228038](https://pubmed.ncbi.nlm.nih.gov/42228038/). *MedScience*. [Clinical Trial Publication]
Watrin T (2026). [PMID: 41048115](https://pubmed.ncbi.nlm.nih.gov/41048115/). *Leuk Lymphoma*. [Review / Meta-Analysis]
Niazi RK (2026). [PMID: 41675759](https://pubmed.ncbi.nlm.nih.gov/41675759/). *Ann Med Surg (Lond)*. [Other]
Troussard X (2025). [PMID: 39710534](https://pubmed.ncbi.nlm.nih.gov/39710534/). *Bull Cancer*. [Review / Meta-Analysis]
AI-curated news mentioning hairy cell leukemia variant
Updated Sep 18, 2026
A case study highlights a disseminated Fusarium infection in a patient undergoing cladribine chemotherapy for hairy cell leukaemia. This finding underscores the potential infectious complications associated with immunosuppressive treatments.
A recent publication provides an update on the diagnosis, risk-stratification, and treatment of hairy cell leukemia, highlighting advancements in understanding the disease. This comprehensive review outlines current best practices and emerging therapies for managing this rare hematological condition.
Recent research indicates that BRAF V600E-mutated marginal zone lymphoma may share characteristics with hairy cell leukemia. This discovery could impact diagnostic approaches and treatment strategies for these overlapping conditions.